



Institutional Biosafety Committee

CDC Institutional Biosafety Committee (IBC) Meeting Minutes

Date: June 26, 2026

Time: 10:30 AM – 12:00 PM

Location: MS Teams meeting

Member	Attendance	Member	Attendance
1. NCEZID/DVBD1	☒	13. NCEZID/DCLSR2	☒
2. NCIRD/DVD	☒	14. IOD/OLSS3	☒
3. NCEZID/DHCPP1	☒	16. NCEZID/DCLSR3	☐
4. IOD/OLSS1	☒	17. NCEZID/OD	☒
5. OCOO/OSSAM/OHC	☐	18. IOD/OLSS4	☒
6. NCEZID/DVBD2	☒	19. NCHHSTP/DHP2	☒
7. IOD/OLSS2	☒	20. Outside Member/Atlanta1	☒
8. NCHHSTP/DHP1	☒	21. Outside Member/Atlanta2	☒
9. NCHHSTP/DTE	☐	22. Outside Member/Fort Collins	☐
10. NCIRD/ID	☐	23. Outside Member/Puerto Rico	☐
11. NCIRD/CORVD	☒	24. CDC/GHC/OD	☒
12. NCEZID/DCLSR1	☐	Visitor(s)	5

Agenda

1. **10:33 am EST**- Welcome and quorum confirmation
2. Confirm quorum
3. Review and approval of **May 15, 2026** Meeting Minutes
4. Review of IBC registrations:
 - 1) IBC-2025-316 Renewal
 - 2) IBC-2026-317 Renewal
 - 3) IBC-2026-318 Renewal
 - 4) IBC-2026-320 Renewal
5. Overview of IBC PULSE Dashboard
6. Discussion on Cross Review Section

Review of IBC Registrations

1. IBC-2025-316 Renewal

General Project Description: This project will develop tools to measure influenza virus and vaccine immunogenicity. We will purify B cells from mice, ferrets, or humans infected with influenza virus, or vaccinated against influenza, or control treated. From the B cells, or from synthetic DNA based on sequences from B cells, we will molecularly clone genes for immunoglobulin heavy and light chains. We will express the immunoglobulins in tissue culture cells and analyze the specificity of the antibody response. Alternatively, we will reprogram the immunoglobulin-coding genes of hybridomas with the CRISPR/Cas9 system to generate stable cell lines for antibody expression.

Approximate percentage of the viral genome used: N/A

Applicable Sec of NIH Guidelines: III-E, III-F-3, III-F-8

Required biological containment level for the work to be implemented: BSL-2



Institutional Biosafety Committee

General Points Discussed:

- **Section 3:** Remove cell lines and add *E. coli* for cloning steps.
- **Section 4.1:** Remove laboratory room numbers.

Committee Action: Approved with changes

2. IBC-2025-317 Renewal

General Project Description: The Arthropod vector activity (also known as Malaria Research and Reference Reagent Resource Center [MR4]) of the BioDefense and Emerging Infections repository (BEI Resources) program, housed in the insectary at the CDC, maintains 50+ different strains for mosquitoes as a source of research materials for scientists worldwide. Of these, twelve are genetically modified. No genetic modifications of these mosquitoes will be done at CDC.

Approximate percentage of the viral genome used: N/A

Applicable Sec of NIH Guidelines: III-D-4a, III-D-8

Required biological containment level for the work to be implemented: BSL-2/ACL-2

General Points Discussed:

- **Section III-D-4:** Clarify use of whole animals; if animals are used, please include IACUC number. If animals are not used, this section should be marked "No."
- **Section 4.1:** Remove laboratory room numbers.

Committee Action: Approved with changes

3. IBC-2025-318 Renewal

General Project Description: The overall goal of this project is to develop genetically modified mosquitoes to be used as an innovative method to control the mosquitoes that transmit the plasmodium parasites that cause human malaria, a disease that causes approximately 600,000 deaths each year. This cutting-edge technology can help prevent disease before reaching our borders. This fits within goals of driving innovation to accelerate new, more effective tools, products and strategies, and technologies. The mosquitoes will be genetically modified in other lab (Imperial College London and PoloGBB). The malaria vector *Anopheles gambiae* and other members of the *Anopheles gambiae* complex have been modified with a homing endonuclease to produce sterile male or male biased strains. Other strains have been modified using a CRISPR Cas9 gene drive that targets the doublesex gene to distort the sex ratio. The CDC lab is maintaining these mosquitoes as back up colonies as well as conducting vector competency studies to ensure that the vector competency has not been altered or improved by the genetic modifications. No further genetic modifications will be done to these mosquitoes at CDC.

Approximate percentage of the viral genome used: N/A

Applicable Sec of NIH Guidelines: III-D-4b, III-D-8

Required biological containment level for the work to be implemented: BSL-2/ACL-2

General Points Discussed:

- **Section III-D-4:** Clarify use of whole animals; if animals are used, please include IACUC number. If animals are not used, this section should be marked "No."
- **Section 4.1:** Remove room numbers.

Committee Action: Approved with changes

4. IBC-2025-320 Renewal

General Project Description: To understand how mutations in Rotavirus genes are contributing to virus adaptation and attenuation, reassortant Rotavirus particles will be generated and the impact of single point mutations in the genome analyzed.

Approximate percentage of the viral genome used: >2/3



Institutional Biosafety Committee

Applicable Sec of NIH Guidelines: III-D-1a, III-D-2a, III-D-3, III-D-4a

Required biological containment level for the work to be implemented: BSL-2

General Points Discussed: N/A

Committee Action: Approved as written

Other Business

- Orientation to the new IBC PULSE Dashboard
 - Developed as a tool to visualize registration analytics in PULSE, track upcoming registrations, and view research trends over time.
 - The dashboard will be deployed to IBC members for user feedback.
- Discussion on Cross Review and consolidating animal information
 - Cross review section is deemed necessary for quality purposes and may be re-named for clarification.
 - Proposal to rename the section to "Reference Check."
 - Deliberated over the need to consolidate animal information in registrations. Further discussions are needed before changes can be implemented.
- Meeting adjourned at 12:02 PM

Reynolds M Salerno, PhD

Director, Office of Laboratory Systems and Response